North America Pulmonary Arterial Hypertension Market Outlook

north america dominates the global pulmonary arterial hypertension (pah) market and is expected to remain the key regional market during the forecast period. the increasing awareness and preference for targeted therapies, a rising number of drug approvals, and strong government support are the major factors driving the market growth in north america. the food and drug administration (fda) has approved various pah drugs, such as tracleer, letairis, adcirca, and opsumit, which are being widely prescribed for the treatment of pah. according to a study, there is an increase in minimum and maximum pah usage among the population suffering from the conditions. the growing prevalence of pah along with the relatively stable commercialization of advanced treatments is augmenting the market’s growth in the u.s. the centers for medicare and medicaid services (cms) has consistently maintained its commitment to ensure pah patients have access to essential therapeutic treatments, thereby providing reimbursement and coverage for pah drugs along with medical services. apart from the government, key players such as actelion pharmaceuticals, teva pharmaceuticals, gilead sciences inc, and glaxosmithkline are also focused on increasing the awareness among consumers about the pervasive existence of pah. tmr report estimates that in 2018, the north american market accounted for 49.3% of the global pah market, followed by europe and asia pacific regions. various strategic initiatives are being taken by the companies to facilitate the market’s growth in north america. for instance, actelion pharmaceuticals has planned to acquire market leader, idorsia, for $30 billion to boost its presence in the sector. moreover, gilead sciences, inc is focusing on expanding its portfolio of pah drugs to encompass a wide range of therapies. these initiatives are likely to fuel the north american pah market going forward.